Related Experiment Video
Updated: Oct 16, 2026

Culture and Imaging of Ex Vivo Organotypic Pseudomyxoma Peritonei Tumor Slices from Resected Human Tumor Specimens
Published on: December 9, 2022
Pleural extension of mucinous tumor in patients with pseudomyxoma peritonei syndrome
S R Pestieau1, J Esquivel, P H Sugarbaker
1Washington Cancer Institute, Washington Hospital Center, Washington, DC 20010, USA.
Background:
Pseudomyxoma peritonei syndrome is a rare disease arising from perforation of an adenoma of the appendix. The syndrome is characterized by progressive accumulation of mucinous fluid and tumor within the abdomen and pelvis. Although this tumor is only superficially invasive and does not metastasize, it is a fatal disease. Extra-abdominal spread of pseudomyxoma peritonei is a rare occurrence, with few reports in the medical literature. This review focuses on pleural extension of mucinous tumor in patients with pseudomyxoma peritonei syndrome.
Methods:
From December 1983 to April 1999, all patients who underwent cytoreductive surgery for pseudomyxoma peritonei syndrome were assessed for pleural involvement at the time of the presentation or follow-up. Clinical information on these patients, including chest computed tomographic scan, was retrospectively reviewed. The mechanisms of extension of mucinous tumor from peritoneal cavity to pleural surface and the results of treatment were of special interest.
Results:
Twenty-three of 426 patients (5.4%) showed pleural extension of pseudomyxoma peritonei syndrome. In four patients (17%), extension into the chest occurred before cytoreductive surgery. In 18 patients, the pleural space was entered during a subdiaphragmatic peritonectomy; and, in 12 patients, extension of disease from peritoneal to pleural space occurred. In six patients (26%), surgical interventions were required to excise tumor that had invaded the hemidiaphragm; and, in the six other patients (26%), there was a minor penetration during subphrenic peritonectomy, which was closed immediately. Finally, in seven patients (30%), the mechanism of spread was unknown. Twelve patients were treated for pleural thoracotomy. Eight patients had an attempt to completely eradicate pleural mucinous tumor, and five patients are currently disease free in the chest (22%); four of these five had intrapleural cytoreduction plus intrapleural chemotherapy. The median survival for all 23 patients is 55 months.
Conclusion:
Pleural spread of pseudomyxoma peritonei syndrome may be a direct result of cytoreductive surgery and the subphrenic peritonectomy procedure. In some patients, dissecting mucinous tumor may infiltrate through the diaphragm and result in pleural extension. Pleural extension of pseudomyxoma peritonei syndrome carries a poor prognosis. Intrapleural chemotherapy combined with cytoreductive surgery may be of considerable value in treatment and prevention of disease dissemination; it should be considered when pleural extension of mucinous tumor is feared or confirmed at the time of cytoreductive surgery.
Insights
Pseudomyxoma peritonei syndrome can spread to the pleura, often during surgery. Intrapleural chemotherapy combined with cytoreductive surgery shows promise for treating this rare but fatal condition.
Area of Science:
- Oncology
- Surgical Oncology
- Gastroenterology
Background:
- Pseudomyxoma peritonei syndrome (PMP) is a rare, fatal condition caused by appendix adenoma perforation, characterized by abdominal mucinous tumor accumulation.
- Extra-abdominal spread of PMP is uncommon, with pleural extension being a rare but significant event.
- This review specifically examines pleural involvement in PMP patients.
Purpose of the Study:
- To investigate the incidence and mechanisms of pleural extension in patients with pseudomyxoma peritonei syndrome.
- To evaluate treatment outcomes and survival for PMP patients with pleural involvement.
Main Methods:
- Retrospective review of 426 patients undergoing cytoreductive surgery for PMP from December 1983 to April 1999.
- Assessment of pleural involvement through clinical information and chest computed tomographic scans.
- Analysis of tumor spread mechanisms and treatment efficacy for pleural disease.
Main Results:
- Pleural extension occurred in 5.4% (23/426) of PMP patients.
- Pleural involvement was noted before surgery in 17% of cases; 50% occurred during subdiaphragmatic peritonectomy.
- Complete eradication of pleural tumor was achieved in 22% of treated patients, with intrapleural cytoreduction and chemotherapy offering the best outcomes. Median survival was 55 months.
Conclusions:
- Pleural spread of PMP can be iatrogenic, resulting from cytoreductive surgery, particularly subphrenic peritonectomy.
- Tumor infiltration through the diaphragm can also lead to pleural extension.
- Intrapleural chemotherapy combined with cytoreductive surgery is a valuable strategy for managing and preventing pleural dissemination in PMP.
Related Concept Videos
Pleural Effusion II: Symptoms and Management
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
Pleural Disorders: Types and Brief Description
Pleura of the Lungs
Pleural Effusion I: Introduction
There are two main types of pleural effusion: transudative and exudative. They are differentiated using Light's criteria,...
Pneumothorax-II
Clinical Manifestations:
Pneumothorax II: Pathophysiology
